Profusa, Baidu, Amylyx Pharmaceuticals, FreeCast and Klarna Group: Why These 5 Stocks Are on Investors' Radars Today

Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

Benzinga Bulls and Bears: Ross, Moderna, Webull

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.

8-K filing — Amylyx Pharmaceuticals, Inc. (AMLX)

Filed: 2026-08-20 AccNo: 0001193125-26-359418 Size: 411 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

Reported Earlier, Amylyx Pharmaceuticals Prices Upsized $500M Public Offering Of 14,090,000 Common Shares At $35.50 Per Share

Brokers Suggest Investing in Baidu Inc. (BIDU): Read This Before Placing a Bet

While brokers maintain a strong buy recommendation for Baidu Inc. with an average brokerage recommendation of 1.65, the Zacks Rank system assigns it a Strong Sell rating due to a 19.3% decline in consensus earnings estimates over the past month. The article cautions that brokerage recommendations often carry positive bias and may not accurately predict stock performance, suggesting investors should rely on earnings estimate revisions rather than broker sentiment.

Baidu shares are trading higher after the company announced it will become a dual-primary listed company on the Hong Kong Stock Exchange in Hong Kong SAR and the Nasdaq Global Select Market in the United States.